Similar articles

• Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.

  Chen CY, Chen WC, Hsu CK, Chao CM, Lai CC. Chen CY, et al. Int Immunopharmacol. 2021 Oct;99:108027. doi: 10.1016/j.intimp.2021.108027. Epub 2021 Jul 31. Int Immunopharmacol. 2021. PMID: 34343937 Free PMC article.
• COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy.

  Khaledi M, Sameni F, Yahyazade S, Radandish M, Owlia P, Bagheri N, Afkhami H, Mahjoor M, Esmaelpour Z, Kohansal M, Aghaei F. Khaledi M, et al. Front Med (Lausanne). 2022 Aug 30;9:961027. doi: 10.3389/fmed.2022.961027. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36111104 Free PMC article. Review.
• JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.

  Nystrom SE, Li G, Datta S, Soldano KL, Silas D, Weins A, Hall G, Thomas DB, Olabisi OA. Nystrom SE, et al. JCI Insight. 2022 Jun 8;7(11):e157432. doi: 10.1172/jci.insight.157432. JCI Insight. 2022. PMID: 35472001 Free PMC article.
• Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials.

  Patoulias D, Doumas M, Papadopoulos C, Karagiannis A. Patoulias D, et al. Clin Rheumatol. 2021 Nov;40(11):4671-4674. doi: 10.1007/s10067-021-05884-4. Epub 2021 Aug 24. Clin Rheumatol. 2021. PMID: 34431004 Free PMC article.
• JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.

  Chen CX, Wang JJ, Li H, Yuan LT, Gale RP, Liang Y. Chen CX, et al. Leukemia. 2021 Sep;35(9):2616-2620. doi: 10.1038/s41375-021-01266-6. Epub 2021 May 14. Leukemia. 2021. PMID: 33990684 Free PMC article.